Categories Earnings, Other Industries

Takeda likely to make a move for Shire

Japanese pharma giant Takeda Pharmaceuticals is said to be planning to bid for London’s leading drug company Shire Pharmaceuticals (Nasdaq: SHPG). The news sent Shire’s stock soaring more than 25% during the morning session in the U.K. market and it surged 18% in the U.S. market.

Shire, which has a market value of around $46.4 billion, focuses on rare disease treatments and hyperactivity medicines. Two months ago, the U.K. drugmaker announced plans to split its business into two divisions.

Shire has been struggling with stiff generic drug competition as well as heavy debt since its acquisition of Baxalta two years ago and has seen its shares drop over 20%. Takeda said the deal would bring opportunities for expansion in rare diseases therapy as well as the areas of neuroscience, oncology and gastrointestinal.

Takeda likely to bid for Shire
Takeda Pharmaceutical Tokyo head office (Courtesy: Wikimedia Commons)

Takeda also sees an opportunity to gain market share in the United States through this deal. Takeda said it has not formally notified Shire of its intentions as the Japanese company is still mulling the various aspects of the deal. There is also no guarantee that a bid or deal will be made.

Takeda has plans to expand its footprint globally and it is looking for more deals and partnerships that will help it move towards this goal. The company wants to find new partners in the area of research and it is also striving to move its products through the pipeline to more advanced stages of development.

Two months ago, the U.K. drugmaker announced plans to split its business into two divisions.

The bid on Shire by Takeda is likely to attract other pharma giants like Pfizer (PFE) or Novartis (NVS) into the bidding arena. The healthcare industry is seeing a number of transactions like GlaxoSmithKline’s (GSK) purchase of Novartis’ stake in their JV and the ongoing bid for Pfizer’s consumer healthcare business.

Most Popular

AVGO Earnings: All you need to know about Broadcom Q1 2021 earnings results

Broadcom Limited (NASDAQ: AVGO) reported first quarter 2021 earnings results today. Total revenue increased 14% year-over-year to $6.65 billion. GAAP net income was $1.3 billion, or $3.05 per share, compared

Infographic: Costco (COST) Q2 2021 sales up 15%; earnings miss

Retail giant Costco Wholesale Corporation (NASDAQ: COST) reported higher earnings and revenues for the second quarter of 2021. Earnings missed analysts’ expectations, while sales beat. Net profit was $951 million

Will shifting to as-a-service model help Hewlett Packard in emerging stronger from COVID?

With the corporate world rapidly shifting to cloud-native computing after the virus outbreak changed work culture and the way businesses operate, technology providers are aggressively innovating their offerings. Hewlett Packard

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top